v3.25.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:      
Research and development $ 360,917 $ 212,928 $ 160,257
Acquired in-process research and development 0 12,500 10,000
General and administrative 77,235 57,281 48,019
Total operating expenses 438,152 282,709 218,276
Interest income (24,732) (24,948) (7,578)
Other (income) expense, net (471) 1,008 253
Loss before provision for income taxes (412,949) (258,769) (210,951)
Provision for income taxes 891 567 9
Net loss $ (413,840) $ (259,336) $ (210,960)
Net loss per common share - basic (in dollars per share) $ (2.73) $ (1.88) $ (1.71)
Net loss per common share - diluted (in dollars per share) $ (2.73) $ (1.88) $ (1.71)
Weighted average common shares outstanding – basic (in shares) 151,573,553 138,100,577 123,075,329
Weighted average common shares outstanding – diluted (in shares) 151,573,553 138,100,577 123,075,329

Source